Davita Inc (NYSE:DVA) Given Consensus Recommendation of “Hold” by Analysts
Shares of Davita Inc (NYSE:DVA) have been assigned a consensus rating of “Hold” from the fourteen analysts that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, nine have issued a hold recommendation and three have given a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $71.38.
Several equities analysts recently commented on the stock. ValuEngine downgraded shares of Davita from a “hold” rating to a “sell” rating in a research note on Friday, May 1st. SunTrust Banks upped their price target on shares of Davita from $82.00 to $90.00 and gave the company a “hold” rating in a research note on Wednesday, May 6th. Royal Bank of Canada restated a “hold” rating and issued a $75.00 price target on shares of Davita in a research note on Monday, April 20th. Finally, Zacks Investment Research upgraded shares of Davita from a “hold” rating to a “buy” rating and set a $89.00 price target on the stock in a research note on Wednesday, June 10th.
Shares of NYSE:DVA traded up $1.93 on Thursday, hitting $79.14. The company had a trading volume of 745,542 shares, compared to its average volume of 1,416,425. Davita has a 1-year low of $50.68 and a 1-year high of $90.15. The stock has a market cap of $9.42 billion, a price-to-earnings ratio of 12.44, a P/E/G ratio of 1.35 and a beta of 1.22. The stock has a 50 day moving average price of $79.92 and a 200 day moving average price of $77.77. The company has a current ratio of 1.81, a quick ratio of 1.77 and a debt-to-equity ratio of 5.24.
In other news, Director Paul J. Diaz sold 5,763 shares of the stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $82.22, for a total value of $473,833.86. Following the completion of the transaction, the director now owns 15,749 shares of the company’s stock, valued at $1,294,882.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Chairman Kent J. Thiry sold 5,390 shares of the stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $81.18, for a total transaction of $437,560.20. Following the completion of the transaction, the chairman now directly owns 283,369 shares of the company’s stock, valued at approximately $23,003,895.42. The disclosure for this sale can be found here. Insiders have sold 12,109 shares of company stock valued at $989,903 in the last ninety days. 1.10% of the stock is currently owned by company insiders.
Hedge funds have recently bought and sold shares of the company. Amundi Pioneer Asset Management Inc. grew its position in shares of Davita by 31.9% during the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 154,693 shares of the company’s stock worth $8,398,000 after buying an additional 37,375 shares during the period. Sei Investments Co. grew its position in shares of Davita by 34.5% during the 4th quarter. Sei Investments Co. now owns 50,805 shares of the company’s stock worth $3,806,000 after buying an additional 13,023 shares during the period. Acadian Asset Management LLC grew its position in shares of Davita by 1,793.5% during the 4th quarter. Acadian Asset Management LLC now owns 6,381 shares of the company’s stock worth $478,000 after buying an additional 6,044 shares during the period. PNC Financial Services Group Inc. grew its position in shares of Davita by 5.6% during the 4th quarter. PNC Financial Services Group Inc. now owns 14,045 shares of the company’s stock worth $1,054,000 after buying an additional 740 shares during the period. Finally, ETRADE Capital Management LLC acquired a new stake in shares of Davita during the 4th quarter worth approximately $346,000. 91.52% of the stock is owned by hedge funds and other institutional investors.
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Featured Article: Support Level
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.